PODD - Insulet Corporation
84.90 0.00 (0.00%)
After hours: 4:47PM EDT
| Previous Close | 86.45 |
| Open | 86.58 |
| Bid | 70.02 x 100 |
| Ask | 103.69 x 100 |
| Day's Range | 83.85 - 87.49 |
| 52 Week Range | 38.43 - 89.63 |
| Volume | 252,573 |
| Avg. Volume | 449,819 |
| Market Cap | 4.982B |
| Beta | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.46 |
| Earnings Date | May 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 90.47 |
Markit•8 days agoSee what the IHS Markit Score report has to say about Insulet Corp.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 9. Over the last one-month, outflows of investor capital in ETFs holding PODD totaled $26 million.
- Thomson Reuters StreetEvents•14 days ago
Edited Transcript of PODD presentation 7-Mar-17 4:35pm GMT
Insulet Corp at Raymond James Institutional Investors Conference
Markit•14 days agoSee what the IHS Markit Score report has to say about Insulet Corp.
Insulet Corp NASDAQ/NGS:PODD
- GlobeNewswire•19 days ago
Report: Developing Opportunities within Insulet, Karyopharm Therapeutics, Playa Hotels & Resorts N.V, Cision Ltd., Freightcar America, and COUPA SOFTWARE — Future Expectations, Projections Moving into 2018
NEW YORK, April 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•19 days ago
Insulet to Announce First Quarter 2018 Financial Results on May 3, 2018
Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the first quarter of 2018 on May 3, 2018 after the close of the financial markets.
- Business Wire•last month
Insulet to Share Omnipod Clinical Data at Three Major European National Diabetes Congresses
Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , announced t
- Benzinga•2 months ago
Analyst: Insulet On Track For Profitability In 2018
Insulet Corporation (NASDAQ: PODD ) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls . The Rating BMO Capital Markets analyst Joanne Wuensch initiated ...
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Public Service Enterprise Group, Nucor, Newmont Mining, Insulet, Hecla Mining, and Occidental Petroleum — Future Expectations, Projections Moving into 2018
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•2 months ago
Insulet Corporation to Present at Upcoming Investor Conferences
Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will presen
Market Realist•2 months agoWhy Abiomed’s Product Pipeline Looks Promising
Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.
- Market Realist•2 months ago
What Analysts Recommend for Abiomed and Peers in February 2018
Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of PODD earnings conference call or presentation 21-Feb-18 9:30pm GMT
Q4 2017 Insulet Corp Earnings Call
Market Realist•2 months agoAnalysts’ Ratings for NxStage Medical and Peers in February 2018
Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.
Motley Fool•2 months agoInsulet Pumps Out 26% Revenue Growth; Loss Narrows
The tubeless insulin pump specialist capped off a strong 2017 with a solid fourth quarter.
- Associated Press•2 months ago
Insulet reports 4Q loss
On a per-share basis, the Billerica, Massachusetts-based company said it had a loss of 12 cents. The results did not meet Wall Street expectations. The average estimate of 13 analysts surveyed by Zacks ...
- Business Wire•2 months ago
Insulet Reports Fourth Quarter Revenue of $130.5 Million, Up 26%, and Gross Margin Up 210 Basis Points, Exceeding Expectations
Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced financial results for the three months and full year ended December 31, 2017.
- ACCESSWIRE•2 months ago
Insulet Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Insulet Corporation (NASDAQ: PODD ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at 4:30 PM Eastern ...
- Benzinga•2 months ago
Insulet Q4 Earnings Preview
Insulet (NASDAQ: PODD ) releases its next round of earnings Wednesday. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report. Earnings and Revenue Insulet's per-share ...
- Business Wire•2 months ago
Insulet Has Strong Presence at the International ATTD Congress; Presents Positive Study Results for Its Omnipod Horizon™ Hybrid Closed-Loop System
Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced promising new data for its Omnipod Horizon™ Automated Glucose Control System hybrid closed-loop system, which will be presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes congress in Vienna, Austria.
- Market Realist•2 months ago
BDX’s Planned Product Launches in 2018
Becton Dickinson's Fiscal 1Q18 Results Beat Analyst Estimates
Markit•2 months agoSee what the IHS Markit Score report has to say about Insulet Corp.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 7. Index (PMI) data, output in the Healthcare sector is rising.
- Market Realist•3 months ago
J&J’s Medical Device Segment Registered Strong Growth in 4Q17
Johnson & Johnson (JNJ) released its 4Q17 and fiscal 2017 results on January 23, 2018. The company reported sales growth across its three business segments: Pharmaceuticals, Medical Devices, and Consumer Businesses. The company’s medical device business contributed ~35% to J&J’s total sales in fiscal 4Q17.
- Business Wire•3 months ago
Insulet Corporation to Announce Fourth Quarter and Full Year 2017 Financial Results on February 21, 2018
Insulet Corporation , the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2017 on February 21, 2018 after the close of the financial markets.
Markit•3 months agoSee what the IHS Markit Score report has to say about Insulet Corp.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 22. Over the last one-month, outflows of investor capital in ETFs holding PODD totaled $89 million.
- Simply Wall St.•3 months ago
Does Insulet Corporation’s (NASDAQ:PODD) Past Performance Indicate A Stronger Future?
Analyzing Insulet Corporation’s (NASDAQ:PODD) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations, whichRead More...
